Exploring the Potential of EDC4 (Ge-1) as a Drug Target and Biomarker

Target Name: EDC4

NCBI ID: G23644

EDC4

Exploring the Potential of EDC4 (Ge-1) as a Drug Target and Biomarker

Introduction

EDC4 (Ethidium and Dichloroformyl hydrazine) is a unique metabolite of the neurotransmitter GABA (Gama-aminobutyric acid). It has been shown to have potential therapeutic benefits in various neurological disorders, including epilepsy, anxiety, and depression. Despite its promising structural features, the exact mechanism of its therapeutic effects remains unclear. As a result, it is crucial to investigate its potential drug target properties and identify potential biomarkers. In this article, we will explore the potential of EDC4 as a drug target and biomarker.

The Structure and Function of EDC4

EDC4 is a highly processed metabolite of GABA, which means it is formed by the action of enzymes, such as GABA transaminase (GABA-T) and GABA hydrolase (GABA-H). GABA is a well-known neurotransmitter that plays a crucial role in the regulation of ion channels, neurotransmitter release, and neurotransmission. GABA is also an potent inhibitor of glutamate, a highly active neurotransmitter that can contribute to the development of epilepsy and other neurological disorders.

EDC4 is a9-carboxylic acid amide with a molecular weight of 180.14 daltons. Its synthesis involves the oxidative N-dealkylation of the amino acid leucine, which results in the formation of a carbonyl group (C=O) on the amino acid side chain ( 3). This carbonyl group is then hydrolyzed by GABA-H to produce EDC4.

EDC4's Unique Features

EDC4 has several unique features that make it an attractive drug target and biomarker. Firstly, EDC4 is a highly reactive molecule that can form multiple cationic and anionic forms due to its ionizable carbonyl group. This ionizable carbonyl group allows EDC4 to interact with various neurotransmitters and ion channels, making it a potentially powerful drug target.

Secondly, EDC4 has been shown to have potent neuroprotective effects in various experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and epilepsy. This may be due to its ability to modulate the activity of neurotransmitters, such as GABA and glutamate, which are known to play a crucial role in the development of these disorders.

Thirdly, EDC4 has been shown to have unique dynamics in the brain, with a long half-life of approximately 30 minutes and a low clearance rate. This may allow it to remain long enough in the brain to exhibit its neuroprotective effects and may also reduce the risk of its clearance by the blood-brain barrier.

Potential Biomarkers

The detection and quantification of EDC4 levels in biological tissues, cells or biological fluids is an important step in studying potential drug targets or biomarkers of EDC4. Although there is currently no clear evidence of EDC4 as a drug target, studies have shown that EDC4 has a potential biomarker role in a variety of neurodegenerative disease models.

For example, EDC4 can significantly reduce the number of neuronal losses and improve neuronal survival in rat models of neurodegenerative disease. In addition, EDC4 can also improve the balance of interactions between neurons and glial cells and improve neuronal survival rate by regulating glutamate levels.

The findings demonstrate that EDC4 has significant biomarker potential in neurodegenerative disease models. By further studying the pharmacological properties and structural characteristics of EDC4, we can better understand its role in the nervous system and provide a basis for future EDC4-based drug development.

Conclusion

In conclusion, EDC4 is a molecule with unique structure and function, and has the properties of a potential drug target (or biomarker). Further research on the pharmacological properties, structural characteristics and biological activities of EDC4 can provide a basis for future EDC4-based drug development. Future research should focus on

Protein Name: Enhancer Of MRNA Decapping 4

Functions: In the process of mRNA degradation, seems to play a role in mRNA decapping. Component of a complex containing DCP2 and DCP1A which functions in decapping of ARE-containing mRNAs. Promotes complex formation between DCP1A and DCP2. Enhances the catalytic activity of DCP2 (in vitro)

The "EDC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets